Molecular mechanisms of hepatocarcinogenesis in chronic hepatitis C virus infection

Journal of Gastroenterology and Hepatology (Australia)

Volumn 26, Issue 6, 2011, Pages 960-964

  Yamashita, Taro ^a   Honda, Masao ^a   Kaneko, Shuichi ^a  

^a KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

Author keywords

Hepatitis C virus; Hepatocellular carcinoma; Transcriptome

Indexed keywords

NONSTRUCTURAL PROTEIN 5A;

ARTICLE; CARCINOGENESIS; GENETIC TRAIT; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INNATE IMMUNITY; LIVER CELL CARCINOMA; MALIGNANT TRANSFORMATION; NONHUMAN; PRIORITY JOURNAL; VIRUS REPLICATION;

EID: 79955898445     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2011.06723.x     Document Type: Article

References (75)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J. Clin. 2005; 55: 74-108.
2. Yang JD, Roberts LR. Hepatocellular carcinoma: a global view. Nat. Rev. Gastroenterol. Hepatol. 2010; 7: 448-58.
3. Thomas DL, Thio CL, Martin MP etal. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461: 798-801.
4. Tillmann HL, Thompson AJ, Patel K etal. A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice. Gastroenterology 2010; 139: 1586-92. 92 e1.
5. Bruix J, Barrera JM, Calvet X etal. Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma and hepatic cirrhosis. Lancet 1989; 2: 1004-6.
6. Colombo M, Kuo G, Choo QL etal. Prevalence of antibodies to hepatitis C virus in Italian patients with hepatocellular carcinoma. Lancet 1989; 2: 1006-8.
7. Liang TJ, Heller T. Pathogenesis of hepatitis C-associated hepatocellular carcinoma. Gastroenterology 2004; 127: S62-71.
8. Yoshizawa H. Hepatocellular carcinoma associated with hepatitis C virus infection in Japan: projection to other countries in the foreseeable future. Oncology 2002; 62 (Suppl. 1): 8-17.
9. Yuen MF, Hou JL, Chutaputti A. Hepatocellular carcinoma in the Asia pacific region. J. Gastroenterol. Hepatol. 2009; 24: 346-53.
10. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132: 2557-76.
11. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004; 127: S35-50.
12. Yu MC, Yuan JM. Environmental factors and risk for hepatocellular carcinoma. Gastroenterology 2004; 127: S72-8.
13. Kawaguchi T, Sata M. Importance of hepatitis C virus-associated insulin resistance: therapeutic strategies for insulin sensitization. World J. Gastroenterol. 2010; 16: 1943-52.
14. Penin F, Dubuisson J, Rey FA, Moradpour D, Pawlotsky JM. Structural biology of hepatitis C virus. Hepatology 2004; 39: 5-19.
15. Tsai WL, Chung RT. Viral hepatocarcinogenesis. Oncogene 2010; 29: 2309-24.
16. Levrero M. Viral hepatitis and liver cancer: the case of hepatitis C. Oncogene 2006; 25: 3834-47.
17. Akuta N, Suzuki F, Kawamura Y etal. Amino acid substitutions in the hepatitis C virus core region are the important predictor of hepatocarcinogenesis. Hepatology 2007; 46: 1357-64.
18. Fishman SL, Factor SH, Balestrieri C etal. Mutations in the hepatitis C virus core gene are associated with advanced liver disease and hepatocellular carcinoma. Clin. Cancer Res. 2009; 15: 3205-13.
19. Moriya K, Fujie H, Shintani Y etal. The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat. Med. 1998; 4: 1065-7.
20. Okuda M, Li K, Beard MR etal. Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein. Gastroenterology 2002; 122: 366-75.
21. Perlemuter G, Sabile A, Letteron P etal. Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral-related steatosis. FASEB J. 2002; 16: 185-94.
22. Kawamura T, Furusaka A, Koziel MJ etal. Transgenic expression of hepatitis C virus structural proteins in the mouse. Hepatology 1997; 25: 1014-21.
23. Wakita T, Taya C, Katsume A etal. Efficient conditional transgene expression in hepatitis C virus cDNA transgenic mice mediated by the Cre/loxP system. J. Biol. Chem. 1998; 273: 9001-6.
24. Lerat H, Kammoun HL, Hainault I etal. Hepatitis C virus proteins induce lipogenesis and defective triglyceride secretion in transgenic mice. J. Biol. Chem. 2009; 284: 33466-74.
25. Ohata K, Hamasaki K, Toriyama K etal. Hepatic steatosis is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C virus infection. Cancer 2003; 97: 3036-43.
26. Kurosaki M, Hosokawa T, Matsunaga K etal. Hepatic steatosis in chronic hepatitis C is a significant risk factor for developing hepatocellular carcinoma independent of age, sex, obesity, fibrosis stage and response to interferon therapy. Hepatol. Res. 2010; 40: 870-7.
27. Yamashita T, Honda M, Takatori H etal. Activation of lipogenic pathway correlates with cell proliferation and poor prognosis in hepatocellular carcinoma. J. Hepatol. 2009; 50: 100-10.
28. Dharancy S, Malapel M, Perlemuter G etal. Impaired expression of the peroxisome proliferator-activated receptor alpha during hepatitis C virus infection. Gastroenterology 2005; 128: 334-42.
29. Waris G, Felmlee DJ, Negro F, Siddiqui A. Hepatitis C virus induces proteolytic cleavage of sterol regulatory element binding proteins and stimulates their phosphorylation via oxidative stress. J. Virol. 2007; 81: 8122-30.
30. Tanaka N, Moriya K, Kiyosawa K, Koike K, Gonzalez FJ, Aoyama T. PPARalpha activation is essential for HCV core protein-induced hepatic steatosis and hepatocellular carcinoma in mice. J. Clin. Invest. 2008; 118: 683-94.
31. Korenaga M, Wang T, Li Y etal. Hepatitis C virus core protein inhibits mitochondrial electron transport and increases reactive oxygen species (ROS) production. J. Biol. Chem. 2005; 280: 37481-8.
32. 2+ uniporter activity. FASEB J. 2007; 21: 2474-85.
33. Furutani T, Hino K, Okuda M etal. Hepatic iron overload induces hepatocellular carcinoma in transgenic mice expressing the hepatitis C virus polyprotein. Gastroenterology 2006; 130: 2087-98.
34. Alisi A, Giambartolomei S, Cupelli F etal. Physical and functional interaction between HCV core protein and the different p73 isoforms. Oncogene 2003; 22: 2573-80.
35. Honda M, Kaneko S, Shimazaki T etal. Hepatitis C virus core protein induces apoptosis and impairs cell-cycle regulation in stably transformed Chinese hamster ovary cells. Hepatology 2000; 31: 1351-9.
36. Kao CF, Chen SY, Chen JY, Lee YHW. Modulation of p53 transcription regulatory activity and post-translational modification by hepatitis C virus core protein. Oncogene 2004; 23: 2472-83.
37. Otsuka M, Kato N, Lan K etal. Hepatitis C virus core protein enhances p53 function through augmentation of DNA binding affinity and transcriptional ability. J. Biol. Chem. 2000; 275: 34122-30.
38. Ray RB, Steele R, Meyer K, Ray R. Hepatitis C virus core protein represses p21WAF1/Cip1/Sid1 promoter activity. Gene 1998; 208: 331-6.
39. Yamanaka T, Kodama T, Doi T. Subcellular localization of HCV core protein regulates its ability for p53 activation and p21 suppression. Biochem. Biophys. Res. Commun. 2002; 294: 528-34.
40. Lee SK, Park SO, Joe CO, Kim YS. Interaction of HCV core protein with 14-3-3epsilon protein releases Bax to activate apoptosis. Biochem. Biophys. Res. Commun. 2007; 352: 756-62.
41. Mohd-Ismail NK, Deng L, Sukumaran SK, Yu VC, Hotta H, Tan YJ. The hepatitis C virus core protein contains a BH3 domain that regulates apoptosis through specific interaction with human Mcl-1. J. Virol. 2009; 83: 9993-10006.
42. Saito K, Meyer K, Warner R, Basu A, Ray RB, Ray R. Hepatitis C virus core protein inhibits tumor necrosis factor alpha-mediated apoptosis by a protective effect involving cellular FLICE inhibitory protein. J. Virol. 2006; 80: 4372-9.
43. Tsutsumi T, Suzuki T, Moriya K etal. Hepatitis C virus core protein activates ERK and p38 MAPK in cooperation with ethanol in transgenic mice. Hepatology 2003; 38: 820-8.
44. Matsuzaki K, Murata M, Yoshida K etal. Chronic inflammation associated with hepatitis C virus infection perturbs hepatic transforming growth factor beta signaling, promoting cirrhosis and hepatocellular carcinoma. Hepatology 2007; 46: 48-57.
45. Wang XW, Hussain SP, Huo TI etal. Molecular pathogenesis of human hepatocellular carcinoma. Toxicology 2002; 181-182: 43-7.
46. Tanji Y, Kaneko T, Satoh S, Shimotohno K. Phosphorylation of hepatitis C virus-encoded nonstructural protein NS5A. J. Virol. 1995; 69: 3980-6.
47. De Mitri MS, Cassini R, Bagaglio S etal. Evolution of hepatitis C virus non-structural 5A gene in the progression of liver disease to hepatocellular carcinoma. Liver Int. 2007; 27: 1126-33.
48. Kasprzak A, Adamek A. Role of hepatitis C virus proteins (C, NS3, NS5A) in hepatic oncogenesis. Hepatol. Res. 2008; 38: 1-26.
49. Benga WJ, Krieger SE, Dimitrova M etal. Apolipoprotein E interacts with hepatitis C virus nonstructural protein 5A and determines assembly of infectious particles. Hepatology 2010; 51: 43-53.
50. Kim K, Kim KH, Ha E, Park JY, Sakamoto N, Cheong J. Hepatitis C virus NS5A protein increases hepatic lipid accumulation via induction of activation and expression of PPARgamma. FEBS Lett. 2009; 583: 2720-6.
51. Kato N, Lan KH, Ono-Nita SK, Shiratori Y, Omata M. Hepatitis C virus nonstructural region 5A protein is a potent transcriptional activator. J. Virol. 1997; 71: 8856-9.
52. Lan KH, Sheu ML, Hwang SJ etal. HCV NS5A interacts with p53 and inhibits p53-mediated apoptosis. Oncogene 2002; 21: 4801-11.
53. Majumder M, Ghosh AK, Steele R, Ray R, Ray RB. Hepatitis C virus NS5A physically associates with p53 and regulates p21/waf1 gene expression in a p53-dependent manner. J. Virol. 2001; 75: 1401-7.
54. Chung YL, Sheu ML, Yen SH. Hepatitis C virus NS5A as a potential viral Bcl-2 homologue interacts with Bax and inhibits apoptosis in hepatocellular carcinoma. Int. J. Cancer 2003; 107: 65-73.
55. He Y, Nakao H, Tan SL etal. Subversion of cell signaling pathways by hepatitis C virus nonstructural 5A protein via interaction with Grb2 and P85 phosphatidylinositol 3-kinase. J. Virol. 2002; 76: 9207-17.
56. Park CY, Choi SH, Kang SM etal. Nonstructural 5A protein activates beta-catenin signaling cascades: implication of hepatitis C virus-induced liver pathogenesis. J. Hepatol. 2009; 51: 853-64.
57. Peng L, Liang D, Tong W, Li J, Yuan Z. Hepatitis C virus NS5A activates the mammalian target of rapamycin (mTOR) pathway, contributing to cell survival by disrupting the interaction between FK506-binding protein 38 (FKBP38) and mTOR. J. Biol. Chem. 2010; 285: 20870-81.
58. Yamashita T, Honda M, Kaneko S. Application of serial analysis of gene expression in cancer research. Curr. Pharm. Biotechnol. 2008; 9: 375-82.
59. Honda M, Kaneko S, Kawai H, Shirota Y, Kobayashi K. Differential gene expression between chronic hepatitis B and C hepatic lesion. Gastroenterology 2001; 120: 955-66.
60. Yamashita T, Kaneko S, Hashimoto S etal. Serial analysis of gene expression in chronic hepatitis C and hepatocellular carcinoma. Biochem. Biophys. Res. Commun. 2001; 282: 647-54.
61. Okabe H, Satoh S, Kato T etal. Genome-wide analysis of gene expression in human hepatocellular carcinomas using cDNA microarray: identification of genes involved in viral carcinogenesis and tumor progression. Cancer Res. 2001; 61: 2129-37.
62. Iizuka N, Oka M, Yamada-Okabe H etal. Comparison of gene expression profiles between hepatitis B virus- and hepatitis C virus-infected hepatocellular carcinoma by oligonucleotide microarray data on the basis of a supervised learning method. Cancer Res. 2002; 62: 3939-44.
63. Honda M, Yamashita T, Ueda T, Takatori H, Nishino R, Kaneko S. Different signaling pathways in the livers of patients with chronic hepatitis B or chronic hepatitis C. Hepatology 2006; 44: 1122-38.
64. Capurro M, Wanless IR, Sherman M etal. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology 2003; 125: 89-97.
65. Jia HL, Ye QH, Qin LX etal. Gene expression profiling reveals potential biomarkers of human hepatocellular carcinoma. Clin. Cancer Res. 2007; 13: 1133-9.
66. Llovet JM, Chen Y, Wurmbach E etal. A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. Gastroenterology 2006; 131: 1758-67.
67. Wurmbach E, Chen YB, Khitrov G etal. Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma. Hepatology 2007; 45: 938-47.
68. Jopling CL, Yi M, Lancaster AM, Lemon SM, Sarnow P. Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. Science 2005; 309: 1577-81.
69. Murakami Y, Aly HH, Tajima A, Inoue I, Shimotohno K. Regulation of the hepatitis C virus genome replication by miR-199a. J. Hepatol. 2009; 50: 453-60.
70. Sarasin-Filipowicz M, Krol J, Markiewicz I, Heim MH, Filipowicz W. Decreased levels of microRNA miR-122 in individuals with hepatitis C responding poorly to interferon therapy. Nat. Med. 2009; 15: 31-3.
71. Pedersen IM, Cheng G, Wieland S etal. Interferon modulation of cellular microRNAs as an antiviral mechanism. Nature 2007; 449: 919-22.
72. Braconi C, Valeri N, Gasparini P etal. Hepatitis C virus proteins modulate microRNA expression and chemosensitivity in malignant hepatocytes. Clin. Cancer Res. 2010; 16: 957-66.
73. Banaudha K, Kaliszewski M, Korolnek T etal. MicroRNA silencing of tumor suppressor DLC-1 promotes efficient hepatitis C virus replication in primary human hepatocytes. Hepatology 2011; 53: 53-61.
74. Ura S, Honda M, Yamashita T etal. Differential microRNA expression between hepatitis B and hepatitis C leading disease progression to hepatocellular carcinoma. Hepatology 2009; 49: 1098-112.
75. Wong QW, Lung RW, Law PT etal. MicroRNA-223 is commonly repressed in hepatocellular carcinoma and potentiates expression of Stathmin1. Gastroenterology 2008; 135: 257-69.